Down but not out: FDA rejects Provention's diabetes drug as commercial product differs from trial drug
In an expected and resolvable setback for Provention Bio, the FDA on July 2 issued a complete response letter for the company’s Type 1 diabetes …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
